Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms

Seminars in Nuclear Medicine

Volumn 26, Issue 1, 1996, Pages 65-73

  Gupta, N ^a   Bradfield, H ^b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18;

ARTICLE; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GASTROINTESTINAL TUMOR; HUMAN; PANCREAS TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029691528     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(96)80017-1     Document Type: Article

References (34)

1. Trenkner SW,Thompson WM:Imaging of gastrointestinal malignancies. Curr Opin Oncol 4:736-740,1992
2. Warburg O:On the origin of cancer cells. Science 123:309-314,1956
3. Phelps ME,Mazziotta JC,Schelbert HR,et al:Positron emission tomography and autoradiography. Principles and Applications for the Brain and Heart. New York,NY,Raven,1986
4. 18F):Nontoxic tracer for rapid tumor detection. J Nucl Med21:670-675,1980
5. Di Chiro G,De La Paz RL,Brooks RA,et al:Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxy-glucose and positron emission tomography. Neurology 32:1323-1329,1982
6. Di Chiro G:Positron emission tomography using [18F]fluoro-deoxyglucose in brain tumors. Invest Radiol 22:360-371,1987
7. Weber G:Enzymology of cancer cells. N Engl J Med296:486-493,541-551,1977
8. Silverberg E. Lubera J:Cancer statistics 1986.CA 36:9-25,1986
9. August DA,Ottow RT,Sugarbaker PH:Clinical perspectives on human colorectal cancer métastases. Cancer Metastasis Rev 3:303-324,1984
10. Sugarbaker PH,Grianola FJ,Dwyer S,et al:A simplified plan for follow up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologie test results. Surgery 102:79-87,1987
11. Moertel CG,Fleming TR,MacDonald JS,et al:An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943-947,1993
12. Schlag P,Uhner B,Strauss LG,et al:Scar or recurrent rectal cancer:Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 324:197-200,1989
13. Strauss LG,Clorius JH,Schlag P,et al:Recurrence of colorectal tumors-PET evaluation. Radiology 17a:329-332,1989
14. Gupta NC,Bowman BM,Frank Al,et al:PET-FDG imaging for follow-up evaluation of treated colorectal cancer. Radiology 199:181P,1991 (abstr)
15. Strauss LG,Conti PS:The applications of PET in clinical oncology. J of Nucl Med32:623-648,1991
16. Hawkins RA:Pancreatic tumore:Imaging with PET1. Radiology 195:320-322,1995
17. Delaloye AB,Wahl RL:How high a level of FDG abdominal activity is considered normal? J of Nucl Med36:106,1995 (abstr)
18. Haberkorn U,Strauss LG,Dimitrakopoulou A,et al:PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med32:1485-1490,1991
19. Gupta NC,Frank Al,Chandramouli B,et al:Clinical role of PET-FDG imaging in evaluation of patients with abdominopelvic malignancies. J of Nucl Med34:55p,1993 (abstr)
20. Gupta NC,Falk PM,Frank AL,et al:Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebraska Medical Journal 26:30-35,1993
21. Gupta N,Frank A,Mailiard J,et al:Accurate detection of liver métastases in patients (PTS) with primary malignancies using PET-FDG imaging. J Nucl Med34:6P,1993
22. Okazumi S,Isorio K,Enomoto K,et al:Evaluation of liver tumors using fluorine- 18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment. J Nucl Med33:333-339,1992
23. Pounds TR,Valk PE,Haseman MK,et al:Whole body PET-FDG imaging in diagnosis of recurrent colorectal cancer. J Nucl Med36:57P,1995
24. Abe Y,Matsuzawa T,Fujiwara T,et al:Assessment of radio-therapeutic effects on experimental tumors using 18F-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med12:325-328,1986
25. Shani J,Wolf W:A model for prediction of chemotherapy response to 5-fluorouracil based on differential distribution of 5-[18F] fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 37:2306-2308,1977
26. Wile AG,Stemmer EA,Andrews PA,et al:Pharmacokinetics of 5-fluoracil during hyperthermic pelvic isolation perfusion. J Clin Oncol 3:849-852,1985
27. Westera G,Reist HW,Buchegger F,et al:Radioimmuno-positron emission tomography with monoclonal antibodies:A new approach to quantifying in vivo tumor concentration and biodistribution for radioimmunotherapy. Nucl MedCommun 12:429-437,1991
28. Eriksson B,Lilja A,Ahlstrom H,et al:Positron emission tomography as a radiological technique in neuroendocrine gastrointestinal tumors. Ann NY Acad Sci 446-456,1991
29. Zeiss J,Coombs RJ,Bielke D:CT presentation and staging accuracy of pancreatic adenocarcinoma. Int J Pancreatol 7:49-53,1990
30. Mackie CR,Cooper MJ,Lewis MJ,et al:Nonoperative differentiation between pancreatic cancer and chronic pancreatitis. Ann Surg 189:480,1979
31. Palazzo L,Roseau G,Gayet B,et al:Endoscopie ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Endoscopy 25:143-150,1993
32. Inokuma T,Tamaki N,Torizuka T,et al:Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US. Radiology 195:345-352,1995
33. Stollfus JC,Glatting G,Friess H,et al:2-(fluorine-18)fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology 195:339-344,1995
34. Alström H,Eriksson B,Bergström M,et al:Pancreatic neuroendocrine tumors:Diagnosis with PET. Radiology 195:2:333-337,1995